Cognitive dysfunction, depression and serum level of brain-derived neurotrophic factor (BDNF) in Egyptian patients with rheumatoid arthritis

Abstract

Aim of the work

To evaluate serum brain-derived neurotrophic factor (BDNF) in Egyptian patients with rheumatoid arthritis (RA) and its relation with cognitive dysfunction.

Patients and methods

The study was carried out on 60 RA patients; 30 were active (group A) and 30 were non active (group B); and 30 controls (group C). RA disease activity was assessed via DAS28 tool, cognitive function via The Montreal Cognitive Assessment and depression via the PHQ depression scale. Serum BDNF levels were measured.

Results

The mean age in group A was 37.8 (± 9.37) years with 83.3% females, in group B was 39.97 (± 8.04) years with 86.7% females and in group C was 33.17 (± 3.6) years with 93.3% females. Abnormal cognitive functions test was detected in 66.7% of group A, 66.7% of group B, and in 23.3% of group C. There was a statistically significant difference in BDNF serum level between both groups of patients (1.58 ± 0.9 ng/ml for group A, 1.81 ± 1.17 ng/ml for group B) compared with the control group (3.01 ± 1.25 ng/ml, p < 0.001).

There was no statistically significant difference between BDNF and both disease duration and cognitive function, also no statistically significant difference regarding cognitive function, depression, and BNDF levels in patients with and without fibromyalgia. At a cut-off value of <2 ng/ml, BDNF detected RA patients with cognitive dysfunction with a sensitivity of 80%, specificity of 96.67%.

Conclusion

BDNF can be a potential biomarker of cognitive dysfunction in RA patients.